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Abstract—A set of closely related furylidene thiosemicarbazones was prepared and screened against various clinically important Gram-
positive bacteria. One compound, containing an ethylene spacer and a 5-nitrofuryl group was found to have promising activity against 
Clostridium difficile. ©2000 Elsevier Science Ltd. All rights reserved. 
The number of reported cases of Clostridium difficile 
associated diarrhoea (CDAD) has increased 
dramatically over the last decade. In 2005, more than 
55, 620 cases of CDAD in patients over the age of 
sixty-five were reported in England, many of which 
were associated with the hypertoxin-producing strain 
ribotype 027. Not surprisingly, C. difficile is now the 
leading hospital associated infection in the UK.
1
 
Furthermore, many strains of C. difficile are now 
emerging with increased resistance and multiple 
resistance to many common antibiotics including 
several fluoroquinolones, erythromycin, 
clarithromycin, fusidic acid and clindamycin.
2,3
 Such 
strains have been associated with outbreaks of CDAD 
in the clinical setting. In light of this, there is a clear 
need to find novel antimicrobial agents with activity 
against both spores and vegetative cells of C. difficile. 
 
Arylidene thiosemicarbazones have been explored in 
recent years for trypanocidal
4-7
, antiamoebic
8
 and 
antibacterial[JMC1967 530] activity. In some of these 
the 5-nitrofuryl moiety has proved to be essential 
either connected directly as the thiosemicarbazone 
derivative or attached via an ethylene spacer. In 
addition, the corresponding copper and palladium 
complexes of these ligands have shown similar or 
enhanced activity against the same targets.
7,8
 We now 
present the biological activities of a set of substituted 
furyl-containing thiosemicarbazones (Scheme1) 
against a panel of Gram-positive bacteria including 
Staphylococcus aureus (methicillin sensitive and 
resistant strains), Staphylococcus epidermidis, 
Propionibacterium acnes and C. difficile. This was 
undertaken with a view to establishing the influence of 
the following structural features on the antimicrobial 
activity: the size of the alkyl group at the N-4 position; 
the presence of a nitro group at the 5-position on the 
furan; the presence of an ethylene spacer group in the 
furylidene portion. 
 
The thiosemicarbazones were prepared in two steps 
using variations on literature procedures
8
. The 
 appropriate isothiocyanates were added to an excess of 
hydrazine in boiling ethanol to give the corresponding 
substituted thiosemicarbazides as crystalline solids 
that precipitated out of the reaction mixture upon 
cooling. These were sufficiently clean to be used in 
the next step without purification. The 
thiosemicarbazides were suspended in ethanol and 
heated at reflux for two hours with 1.3 molar 
equivalents of the appropriate furyl aldehyde to give 
the target compounds 1 –12 (Scheme 1 and Table 1). 
Again, these compounds precipitated cleanly out of 
the reaction mixture. By this simple procedure the 
nitrofuranyl compounds (1 – 4, 6, 8, 10, 12) were 
obtained in 59 – 93% yield and the furanyl compounds 
(5, 7, 9, 11) in 27-57% yield. The compounds were 
characterised by melting point, infra-red spectroscopy, 
mass spectrometry (+ve electrospray accurate mass) 
and proton NMR spectroscopy and had properties 
consistent with the proposed structures. 
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Scheme 1. Preparation of the target thiosemicarbazones (Compounds 1 
– 12) 
 
 
Table 1. Structures of the compounds synthesised and screened in this 
study. 
Compound R1 n R2 cLogPa Ref. 
1 Me 0 NO2 2.1 6, 7, 9 
2 Et 0 NO2 2.4 6, 7, 9 
3 i-Pr 0 NO2 2.8 7, 8 
4 t-Bu 0 NO2 2.9  
5 Me 1 H 1.7  
6 Me 1 NO2 2.5 6, 7, 9 
7 Et 1 H 2.1  
8 Et 1 NO2 2.8 6, 7, 9 
9 i-Pr 1 H 2.5  
10 i-Pr 1 NO2 3.2 10 
11 t-Bu 1 H 2.5  
12 t-Bu 1 NO2 3.3 11 
aCAChe WorkSystem Pro Version 6.1.12.33 (Fujitsu Ltd) 
 
The test compounds were solubilised in DMSO and 
diluted with nutrient broth (Oxoid Ltd) prior to 
screening for 24h at 37 C against an initial panel of 
organisms in using 2.5 x 10
7
 CFU/mL. Anaerobic 
microorganisms were incubated in an anaerobic 
cabinet. Controls consisted of incubations of the 
specified organisms as above but omitting the test 
compounds. Compound 8 was tested further against an 
expanded panel of organisms. The resulting minimum 
inhibitory concentrations are presented in Tables 2 and 
3. Vancomycin susceptibility was investigated for a 
sub-set of organisms and the results are presented in 
Table 2. A suspension of each organism (at a 
concentration of McFarland 0.5) was used to inoculate 
the entire surface of appropriate agar plates. 
Vancomycin E-test strips (AB BIODISK, Solna, 
Sweden) were place in the middle of the agar plates 
and incubated under the appropriate conditions: 
Staphylococci, Nutrient agar (Oxoid, UK) plates, 37 
C, aerobic, 24 h; C. difficile, Wilkins Chlagren agar 
WCA (Oxoid, UK) plates, 37 C, anaerobic, 48 h; P. 
acnes, Nutrient agar plates, 37 C, anaerobic, 48 h. 
 
Compounds 1-12 were screened against an initial 
panel of Gram-positive organisms in nutrient broth 
that included representative strains of C. difficile, S. 
epidermidis, S. aureus (including MRSA strains) and 
P.  acnes (Table 2). Compound 8 was significantly 
more active against each of the different types of 
organism. This can be seen in Figure 1 where the 
reciprocal of the averaged MIC values for the different 
types of organism for each of the compounds has been 
presented as a bar chart. Excluding P. acnes, the 
structure activity profile was quite sharp. Apart from 
compound 8 only compounds 1, 2 and 6 had 
noticeable antimicrobial activity. Each of these four 
compounds has the 5-nitrofuran moiety. For P. acnes, 
again, compound 8 was the most active but this time 
moderate antimicrobial activity was spread across the 
test compounds with the exception of 3, 7 and 9.  
 
Thiosemicarbazones of 5-nitro-2-furaldehyde also 
containing N-4 dialkyl/cycloalkyl substituents are 
known to have antifungal properties and activity 
against mainly Gram-positive bacteria [JMC1967]. 
For example, the N-4 diethyl analogue of compound 2 
has good activity against E. coli, M. pyogenes, S. 
pyogenes, B. subtilis and moderate activity against T. 
mentagrophytes and C. albicans. Although these are 
different organisms from those presented in this article 
it appears that the addition of a second alkyl 
substituent at the N-4 position of the 
thiosemicarbazones without the ethylene spacer (n=0) 
improves activity against Gram-positive bacteria.  
 
Compound 8 was tested against an expanded panel of 
organisms (Table 3). It had good activity against the 
organisms mentioned above. For C. difficile in 
particular the reference strain NCTC 11204 was 
inhibited at 4-8 g/mL and a set of thirty-three clinical 
strains exhibited minimum inhibitory concentrations in 
the range 0.125-0.25 to 16-32 g/mL. In addition, no 
activity was observed against the Gram-negative 
bacterium Acinetobacterium or C. albicans yeast 
strains. 
 
 The mechanism of action of the lead compound 8 is 
unknown at this time. On the basis that the LogP 
values for the inactive compounds 3, 4, 6, 9, 10 and 11 
(Table 1) are very similar to that of the active 
compound 8, it may be expected that the cellular 
penetrations of these compounds are be similar. Thus 
the observed SAR may indeed be because of 
interactions at particular targets rather than differences 
in cellular penetration. In addition the acute in vivo 
toxicity of compounds 2 and 8 indicated nontoxic 
effects on the basis of clinical biochemistry, 
haematology and the histological studies of organs.
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In summary, amongst a set of closely related 
thiosemicarbazones, compound 8 was found to have 
promising antimicrobial activity against clinically 
important Gram-positive skin organisms. Its key 
structural features included an ethyl group at N-4, an 
ethylene spacer in the furylidene portion and a nitro 
group at the 5-position of the furan ring.  
 
 
Table 2. Minimum inhibitory concentration ( g mL-1) of compounds 1-12 against an initial panel of organisms. 
 Compounds 
Organisms 1 2 3 4 5 6 7 8 9 10 11 12 Vanc.a 
C.  difficile NCTC11204 >256 64-128 >256 128-256 >256 64-128 >256 4-8 >256 >256 >256 >256 0.5 
C. difficile O27 64-128 64-128 64-128       >256 64-128 32-64 64-128 8-16 64-128 64-128 64-128 64-128 0.75 
C. difficile Z162 >256 128-256 >256 128-256 >256 32-64 >256 
0.125- 
0.25 >256 >256 >256 128-256  
C. difficile Z229 64-128 8-16 128-256 16-32 128-256 16-32 64-128 4-8 128-256 64-128 64-128 64-128  
S. epidermidis NCTC 11047 16-32 32-64 64-128 128-256       >256 32-64       >256 4-8       >256 64-128       >256       >256 2 
S. epidermidis 9 128-256 64-128       >256       >256       >256 64-128       >256 1-2       >256       >256       >256       >256  
S .epidermidis 4 32-64 32-64       >256       >256 128-256 32-64       >256 4-8       >256 64-128       >256       >256  
S. aureus ATCC 6538 64-128 32-64 64-128 64-128       >256 32-64       >256 4-8       >256       >256       >256       >256 1.5 
S. aureus  H1 64-128 16-32 128-256       >256       >256 16-32       >256 16-32       >256 256       >256 64-128  
S.aureus K1 128-256 64-128       >256 64-128       >256       >256       >256 4-8       >256       >256       >256 32-64  
MRSA A1 64-128 64-128       >256       >256       >256 64-128       >256 2-4       >256       >256       >256       >256  
MRSA C3       >256 64-128       >256       >256       >256 64-128       >256 4-8       >256       >256       >256       >256  
MRSA E1 64-128 64-128       >256       >256       >256 64-128       >256 4-8       >256       >256       >256       >256  
P. acnes NCTC 737  16-32 16-32 64-128 64-128 32-64 16-32 16-32 4-8 32-64 32-64 64-128 16-32 0.5 
P. acnes B5 64-128 32-64       >256 32-64 32-64 1-2       >256 8-16       >256 32-64 64-128 32-64  
P. acnes C3 16-32 2-4 32-64 16-32 16-32 1-2 32-64 2-4 1-2 32-64 4-8 8-16  
P. acnes C5 64-128 32-64 64-128 16-32 1-2 64-128 32-64 32-64 64-128 64-128 1-2 16-32  
a Vancomycin  
 
Table 3. Minimum inhibitory concentration ( g mL-1) of compound 8 against an expanded panel of organisms. 
Organism MIC  Organism MIC  Organism MIC 
C. difficile Z16 8-16  C. difficile Z179 2-4  MRSA A3 4-8 
C. difficile Z21 16-32  C. difficile Z251 1-2  MRSA B1 4-8 
C. difficile Z 66 4-8  C. difficile Z387 16-32  MRSA B3 4-8 
C. difficile Z150 4-8  C. difficile Z1568 1-2  MRSA D1 4-8 
C. difficile Z158 2-4  C. difficile Z1577 0.5-1  MRSA C1 2-4 
C. difficile Z159 8-16  C. difficile Z1578 1-2  EMRSA 15 4-8 
C. difficile Z160 8-16  C. difficile Z1579 2-4  P. acnes B3 8-16 
C. difficile Z161 0.5-1  C. difficile Z1580 1-2  P. acnes C1 8-16 
C. difficile Z163 2-4  C. difficile Z1591 1-2  P. acnes D1 4-8 
C. difficile Z164 1-2  S. epidermidis NCTC 9865 2-4  P. acnes D3 4-8 
C. difficile Z166 2-4  S. epidermidis RP62A 4-8  C. albicans 1013781 128-256 
C. difficile Z167 2-4  S. epidermidis 3 2-4  C. albicans 1012155 128-256 
C. difficile Z168 2-4  S. epidermidis 7A 2-4  C. albicans 1009116 128-256 
C. difficile Z169 2-4  S. epidermidis 8A 2-4  C. albicans 1011377 128-256 
C. difficile Z170 2-4  S. epidermidis 10 4-8  C. albicans 1015391 128-256 
C. difficile Z171 2-4  S. epidermidis 11 1-2  Acinetobacterium spp. 1 128-256 
C. difficile Z172 4-8  S. aureus T1 4-8  Acinetobacterium spp. 2 128-256 
C. difficile Z173 8-16  S. aureus V1  2-4  Acinetobacterium spp. 2 128-256 
C. difficile Z175 0.5-1  S. aureus  H1 64-128  Acinetobacterium spp. 4 128-256 
C. difficile Z176 2-4  S. aureus MSSA2 4-8  Acinetobacterium spp. 5 128-256 
C. difficile Z177 2-4  S. aureus MSSA3 4-8    
 
  
 
Figure 1. . Bar chart of averaged 1/MIC values (mL g-1) for compounds 1-12 for the various classes of organisms tested. 
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10. 4-(i-Propyl)-1-[3-(5-nitrofuryl)propenilidene]thiosemi 
carbazide (10) 
Dark red powder. 86% Yield. Melting Point 219.4-222.0 
C (corrected). 
1
H NMR (D6-DMSO; δDMSO = 2.50ppm) 
1.18 (6H, d, J=6.9 Hz, Me2), 4.47 (1H, m, CHMe2), 7.04 
(3H, overlapping m, Furan-H3 & N=CH-CH=CH), 7.75 
(1H, d, J=3.8 Hz, Furan-H4), 7.86 (1H, dd, J=6.95 1.90 
Hz, N=CH-CH), 8.15 (1H, d, J=8.9Hz, Me2CHNH), 11.62 
(s, 1H, NH-N=C) ppm. IR (KBr) 3358, 3320, 3123, 2971, 
1531, 1464, 1347, 1231, 1190 cm
-1
. High resolution MS 
(+electrospray): (M+H)
+
 calc 283.0865, found 283.0845. 
11. 4-(t-Butyl)-1-[3-(5-nitrofuryl)propenilidene]thiosemi 
carbazide (12) 
Orange powder. 93% Yield.  Melting Point decomp. 209.5 
C (Corrected). 
1
H NMR (D6-DMSO; δDMSO = 
2.50ppm), 1.51 (9H, s, Me3), 7.02 (2H, overlapping m, 
N=CH-CH=CH), 7.08 (d, J=3.8 Hz, 1H, Furan-H3), 7.57 
(1H, s, NHCMe3), 7.76 (1H, d, J=4.4 Hz, Furan-H4), 7.87 
(dd, J=5.06 3.16 Hz, 1H, N=CH-CH), 11.56 (s, 1H, NH-
N=C) ppm. IR (KBr) 3312, 3142, 2973, 1529, 1509, 1466, 
1417, 1390, 1355, 1260, 1241 cm
-1
. High resolution MS 
(+electrospray): (M+H)
+
 calc 297.1021, found 297.1013. 
